WS Management’s Audentes Therapeutics, Inc BOLD Stock Holding History

WS Management’s Portfolio BOLD Stock Details BOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-118,421	Closed	-$3.33M	–	68
2019 Q3	$3.33M	Sell	118,421 -13,074	-10%	-$446K	0.26%	48
2019 Q2	$4.98M	Sell	131,495 -12,527	-9%	-$481K	0.32%	52
2019 Q1	$5.62M	Sell	144,022 -22,868	-14%	-$656K	0.34%	47
2018 Q4	$3.56M	Sell	166,890 -74,110	-31%	-$1.91M	0.17%	56
2018 Q3	$9.54M	Hold	241,000	–	–	0.31%	48
2018 Q2	$9.21M	Buy	+241,000	New	+$8.93M	0.26%	48

Other funds holding BOLD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

WS Management's BOLD Position: Q4 2019 in Review

WS Management sold out of Audentes Therapeutics, Inc (BOLD) in Q4 2019, closing a stake of 118,421 shares — an estimated $3.33M sold.

WS Management first reported a position in BOLD in Q2 2018 and held it in 6 quarters. The position peaked at $9.54M in Q3 2018. 188 funds tracked by Wall St. Rank hold BOLD as of Q4 2019.

WS Management reported no remaining Audentes Therapeutics, Inc position as of Q4 2019 after selling out during the quarter.
WS Management sold 118,421 Audentes Therapeutics, Inc shares in Q4 2019, an estimated $3.33M.
WS Management first reported a position in Audentes Therapeutics, Inc in Q2 2018 and held it in 6 quarters.
WS Management's Audentes Therapeutics, Inc position peaked at $9.54M in Q3 2018.
188 funds tracked by Wall St. Rank held Audentes Therapeutics, Inc as of Q4 2019.

Based on WS Management's 13F filing for Q4 2019, filed 12 Feb 2020.